250,868 results match your criteria Lymphoma Bone


Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients with ALK-positive NSCLC Following Treatment with Crizotinib.

J Thorac Oncol 2018 Dec 3. Epub 2018 Dec 3.

Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.

Introduction: The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally available small-molecule tyrosine kinase inhibitor, crizotinib in the real-world clinical setting.

Methods: Post-marketing surveillance was performed in Japan to obtain information on the safety and efficacy of crizotinib. Target patients included all patients with anaplastic lymphoma kinase-positive non-small cell lung cancer (NSCLC) who received crizotinib, during the enrollment period between May 2012 and December 2014. Read More

View Article
December 2018
3 Reads

MiR-15b is a key regulator of proliferation and apoptosis of chondrocytes from patients with condylar hyperplasia by targeting IGF1, IGF1R and BCL2.

Osteoarthritis Cartilage 2018 Dec 3. Epub 2018 Dec 3.

Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei province, China. Electronic address:

Objective: This study aimed to explore potential microRNAs (miRNAs), which participate in the pathological process of condylar hyperplasia (CH) through targeting specific proliferation- and apoptosis-related genes of chondrocytes.

Methods: Insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1R) and B-cell CLL/lymphoma 2 (BCL2) in CH cartilage were detected by real-time PCR, Western blot, immunohistochemistry and immunofluorescence. MiRanda and TargetScanS algorithms were used to predict certain miRNAs in CH chondrocytes concurrently modulating the above three genes. Read More

View Article
December 2018
1 Read

Pemphigus and hematologic malignancies: A population-based study of 11,859 patients.

Authors:
Eden Lake

J Am Acad Dermatol 2018 Dec 3. Epub 2018 Dec 3.

Loyola University Medical Center Dermatology, 321 N La Grange Rd, La Grange Park, IL. Electronic address:

•Hematologic malignancies have been reported sporadically in patients with pemphigus.•In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.•Further research is needed to confirm these findings in other cohorts. Read More

View Article
December 2018
2 Reads

Two Double-hit Lymphomas Cases: A Molecular Cytogenetic Approach.

J Assoc Genet Technol 2018 ;44(4):141-145

Allina Health, Minneapolis, MN.

Objectives: Double-hit lymphomas represent 5% of cases of diffuse large B-cell lymphomas (DLBCL). They are currently recognized as highgrade B-cell lymphomas (HGBCL) with rearrangements of MYC and BCL2 and/or BCL6 by the 2016 WHO classification. One of these rearrangements is the translocation of the BCL2 gene (18q21. Read More

View Article
January 2018
1 Read

Kinetically selective and potent inhibitors of HDAC8.

Biol Chem 2018 Dec 1. Epub 2018 Dec 1.

Department of Chemical Engineering and Biotechnology, University of Applied Sciences Darmstadt, 64295 Darmstadt, Germany.

HDAC8 is an established and validated target for T-cell lymphoma and childhood neuroblastoma. The active site binding pocket of HDAC8 is highly conserved among all zinccontaining representatives of the histone deacetylase family. This explains that most HDACs are unselectively recognized by similar inhibitors featuring a zinc binding group (ZBG), a hydrophobic linker and a head group. Read More

View Article
December 2018

Histological Subtypes and Clinical Behavior Evaluation of Salivary Gland Tumors.

Acta Med Port 2018 Nov 30;31(11):641-647. Epub 2018 Nov 30.

Department of Pathology. Centro Hospitalar São João. Porto. Unit of Pathology and Oncology. Department of Pathology. Faculdade de Medicina. Universidade do Porto. Porto. Portugal.

Introduction: Salivary gland tumors include a wide spectrum of histological subtypes and clinical behavior, which we aim to evaluate.

Material And Methods: We performed a retrospective study of all salivary gland tumors diagnosed and treated at the Centro Hospitalar São João, Porto, between 2005 and 2015. Histological re- evaluation was performed in all cases and patient files were reviewed and both clinical and follow-up data were collected. Read More

View Article
November 2018
3 Reads

Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center.

Breast J 2018 Dec 6. Epub 2018 Dec 6.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York.

Purpose: Evaluate the clinical presentation and imaging findings of breast implant-associated anaplastic large cell lymphoma (BIA ALCL) at a large US cancer center.

Materials And Methods: HIPAA-compliant IRB approved retrospective study, for which informed consent was waived. The Hospital Information System was screened for women who underwent implant reconstruction and were diagnosed with BIA ALCL between 2010 and 2016. Read More

View Article
December 2018

Coexistence of systemic lupus erythematosus with Kikuchi-Fujimoto disease involving the salivary gland, initially disguised as lymphoma.

Rheumatology (Oxford) 2018 Dec 5. Epub 2018 Dec 5.

Division of Rheumatology, Department of Internal Medicine, Jeonju, Republic of Korea.

View Article
December 2018

CD8-positive lymphomatoid papulosis (type D): Some lesions may lack CD30 expression and overlap histologically with mycosis fungoides.

Int J Dermatol 2018 Dec 6. Epub 2018 Dec 6.

School of Medicine, Indiana University, Indianapolis, IN, USA.

Background: CD8 lymphomatoid papulosis is frequently indistinguishable histopathologically from primary cutaneous aggressive epidermotropic CD8 T-cell lymphoma except for the expression of CD30. However, absent or weak expression of CD30 has been rarely reported in cases of CD8 LyP.

Objective: We aim to study the clinical and pathologic features of cases of CD8 LyP with no or minimal expression of CD30. Read More

View Article
December 2018

Trends in the incidence and mortality of cancer in Saudi Arabia.

Saudi Med J 2018 Dec;39(12):1259-1262

Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia. E-mail.

Objectives: To analyze the overall trends in cancer incidence and mortality in Saudi Arabia between 1990 and 2016.   Methods: Data were retrieved through a Global Burden of Disease (GBD, 2016) database (Viz Hub) that is developed by the Institute for Health Metrics and Evaluation at the University of Washington. Results: The incidence of cancer increased around 26-fold for thyroid cancer; approximately 10-fold in breast, colon, bladder and uterine cancers; 8-fold for prostate cancer; 5-fold for renal cancer; 4-fold for pancreatic and ovarian cancer; 3. Read More

View Article
December 2018

Dermoscopic follow-up of therapeutic response in mantle cell lymphoma with secondary involvement of the scalp.

J Cosmet Dermatol 2018 Dec 5. Epub 2018 Dec 5.

The Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland.

The scalp is a potential location for both benign and malignant tumors. Lymphoproliferative diseases can involve the skin as a primary or secondary manifestation. Dermoscopy is a noninvasive diagnostic tool for rapid diagnosis, screening, and follow-up of the majority of skin tumors. Read More

View Article
December 2018
2 Reads

Brentuximab induced CD30+ cutaneous lymphoma responded to anti-PD1 treatment.

J Eur Acad Dermatol Venereol 2018 Dec 6. Epub 2018 Dec 6.

Dermatology Department, Cutaneous Lymphoma Clinic, National& Kapodestrian University of Athens, Medical School, "A. Sygros" Hospital for skin diseases, Athens, Greece.

Over the last decade major efforts have been made for the optimization of immune-directed therapies against cancer. Regarding cutaneous lymphomas (CTCLs), brentuximab (BV) has been recently approved by FDA and EMA for the treatment of primary cutaneous anaplastic large cell lymphoma as well as CD30-expressing mycosis fungoides, based on the ALCANZA trial favorable results. Concurrently, immune checkpoint inhibition has been shown to be of great value in the treatment of solid tumors and with promising results in a range of hematologic malignancies, however relevant data concerning CTCLs' treatment remain inconclusive. Read More

View Article
December 2018
1 Read

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Br J Haematol 2018 Dec 5. Epub 2018 Dec 5.

Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE, USA.

Relapsed or refractory non-Hodgkin lymphomas (NHLs) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad-spectrum multi-kinase inhibitor in relapsed/refractory NHL with correlative genomic analysis in a Phase I/II trial. The study included 33 patients with various sub-types of NHL who had received at least one prior therapy. Read More

View Article
December 2018
3 Reads

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.

Br J Haematol 2018 Dec 5. Epub 2018 Dec 5.

Department of Haematology, Oncology, Haemostaseology, and Pneumology, University Hospital, Münster, Germany.

To further improve outcome in young high-risk patients with diffuse large B-cell lymphoma (DLBCL) the number of rituximab (R) infusions was doubled in combination with standard CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone) chemotherapy. Seventy-seven patients (aged 18-60 years) with an age-adjusted International Prognostic Index of 2-3 received 12 × R (375 mg/m ) on days 0, 1, 4, 8, 15, 22, 29, 43, 57, 71, 85 and 99 together with eight cycles of CHOEP-14. Results were retrospectively compared to those of patients receiving 6 × R and 8 × CHOEP-14 in the standard arm of the randomized R-MegaCHOEP trial. Read More

View Article
December 2018

Villous lymphocytes in splenic large B-cell lymphoma with diffuse red pulp infiltration.

Int J Hematol 2018 Dec 5. Epub 2018 Dec 5.

Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

View Article
December 2018

CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients.

Open Med (Wars) 2018 27;13:605-609. Epub 2018 Nov 27.

Department of Internal Medicine 5th Division Jiangxi Cancer Center, Jiangxi Cancer Hospital, Nanchang University, Nanchang, 330029 P.R. China.

Objective: To investigate the expression and clinical significance of CD5 and CD43 in diffuse large B cell lymphoma (DLBCL) (unspecified).

Methods: Sixty - five patients with diagnosed DLBCL were enrolled. The expressions of CD5, CD43, CD10, Bcl-6 and Mun-1 were detected by immuno histochemistry. Read More

View Article
November 2018

Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth.

J Cancer 2018 31;9(23):4503-4509. Epub 2018 Oct 31.

Department of Pediatrics, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.

Kaposi's Sarcoma-associated Herpesvirus (KSHV) is the etiologic agent of several human malignancies, particularly Kaposi's Sarcoma (KS), which preferentially arise in immunocompromised patients such as HIV+ subpopulation while still lacking of effective therapeutic options. We recently found that the ribonucleotide reductase (RR) subunit M2 is potentially regulated by the key oncogenic HGF/c-MET pathway in KSHV-related lymphoma cells. One of RR inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) effectively induced apoptosis of KSHV+ lymphomas and suppressed tumor progression . Read More

View Article
October 2018

Ly9 (CD229) Antibody Targeting Depletes Marginal Zone and Germinal Center B Cells in Lymphoid Tissues and Reduces Salivary Gland Inflammation in a Mouse Model of Sjögren's Syndrome.

Front Immunol 2018 16;9:2661. Epub 2018 Nov 16.

Immunology Unit, Department of Biomedical Sciences, Medical School, University of Barcelona, Barcelona, Spain.

Sjögren's Syndrome (SjS) is a common chronic autoimmune disease characterized by the B cell hyperactivation, lymphocyte infiltration, and tissue damage of exocrine glands. It can also present life-threatening extraglandular manifestations, such as pulmonary and hepatic involvement, renal inflammation and marginal zone (MZ) B cell lymphoma. Several biologic agents have been tested in SjS but none has shown significant efficacy. Read More

View Article
November 2018

Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement.

Case Rep Oncol 2018 Sep-Dec;11(3):721-728. Epub 2018 Nov 12.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Background: Involvement of the central nervous system (CNS) by mycosis fungoides (MF) is rare; however, it portends a poor prognosis. While aggressive multimodality therapy may improve outcomes, the role of radiation therapy (RT) is not well defined.

Objectives: We sought to explore the efficacy of RT in the management of CNS involvement by MF. Read More

View Article
November 2018

Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.

Leukemia 2018 Dec 5. Epub 2018 Dec 5.

Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167, Rome, Italy.

Sézary syndrome (SS) is a rare and aggressive variant of Cutaneous T-Cell Lymphoma characterized by neoplastic distribution mainly involving blood, skin, and lymph-node. Although a role of the skin microenvironment in SS pathogenesis has long been hypothesized, its function in vivo is poorly characterized. To deepen this aspect, here we compared skin to blood-derived SS cells concurrently obtained from SS patients highlighting a greater proliferation-index and a PI3K/AKT/mTORC1 pathway activation level, particularly of mTOR protein, in skin-derived-SS cells. Read More

View Article
December 2018
1 Read

Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.

Cell Death Dis 2018 Dec 5;9(12):1178. Epub 2018 Dec 5.

Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.

Cutaneous T-cell lymphoma is a group of incurable extranodal non-Hodgkin lymphomas that develop from the skin-homing CD4 T cell. Mycosis fungoides and Sézary syndrome are the most common histological subtypes. Although next-generation sequencing data provided significant advances in the comprehension of the genetic basis of this lymphoma, there is not uniform consensus on the identity and prevalence of putative driver genes for this heterogeneous group of tumors. Read More

View Article
December 2018

CD19-directed CAR T cells gain traction.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Perelman Center for Advanced Medicine, 34th and Civic Center Blvd, Philadelphia, PA 19104, USA. Electronic address:

View Article
November 2018

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol 2018 Nov 30. Epub 2018 Nov 30.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a median follow-up of 15·4 months (IQR 13·7-17·3), 89 (82%) of 108 assessable patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel achieved an objective response, and complete responses were noted in 63 (58%) patients. Here we report long-term activity and safety outcomes of the ZUMA-1 study. Read More

View Article
November 2018

Ulmus macrocarpa Hance improves benign prostatic hyperplasia by regulating prostatic cell apoptosis.

J Ethnopharmacol 2018 Nov 30. Epub 2018 Nov 30.

Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam National University, Daejeon. Electronic address:

Ethnopharmacological Relevance: Ulmus macrocarpa Hance (UMH), of the family Ulmaceae, is a deciduous tree, widely distributed throughout Korea. UMH has been used as a traditional oriental medicine in Korea for the treatment of urological disorders, including bladder outlet obstrulmition (BOO), lower urinary tract syndrome (LUTS), diuresis, and hematuria. To date, its possible protective effects against benign prostatic hyperplasia (BPH) have not been analyzed. Read More

View Article
November 2018

Fludarabine/melphalan 100 mg/m Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.

Biol Blood Marrow Transplant 2018 Nov 30. Epub 2018 Nov 30.

Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Our previous research indicated that a reduced-intensity conditioning regimen (fludarabine and melphalan at 100 mg/m) was useful in allogeneic hematopoietic cell transplantation (HCT) for patients with lymphoma. This retrospective study evaluated the reduced-intensity conditioning regimen in allogeneic HCT for adult patients with hemophagocytic lymphohistiocytosis (HLH). Sixteen patients with HLH were evaluated, including 6 patients who were enrolled in a prospective clinical trial (NCT00772811) and 10 patients who received the same conditioning regimen (fludarabine at 30 mg/m/day on days -6 to -2 and melphalan at 100 mg/m on day -2). Read More

View Article
November 2018
1 Read

Primary Non-Hodgkin Lymphoma of the Parotid Gland Masquerading Chronic Sialadenitis.

J Craniofac Surg 2018 Nov 30. Epub 2018 Nov 30.

Oral and Maxillofacial Surgery, 8AFDC, Kanpur, India.

View Article
November 2018

Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.

Leuk Lymphoma 2018 Dec 3:1-7. Epub 2018 Dec 3.

a Department of Internal Medicine , Seoul National University Hospital , Seoul , Korea.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been the only treatment option for acute myeloid leukemia (AML) refractory to induction chemotherapy, with only 10-20% of patients achieving long-term survival. Certain donor genotypes may confer leukemia-clearing effects after allo-HSCT. We performed whole-exome sequencing of five pairs of the germ lines in AML patients who achieved long-term remission after allo-HSCT and in their donors, and found two significant variants: EGFR c. Read More

View Article
December 2018
1 Read

Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group.

Leuk Lymphoma 2018 Dec 3:1-10. Epub 2018 Dec 3.

a German Hodgkin Study Group (GHSG), Department of Internal Medicine I , University Hospital of Cologne , Cologne , Germany.

We performed a survey in Hodgkin lymphoma survivors to learn more about their perspectives on treatment risks and benefits. We sent questions to 1149 survivors from the GHSG's HD13-15 trials with (N = 249) or without (N =900) documented progression or relapse. The participation rate was 52% (N =581). Read More

View Article
December 2018

Value of CT spectral imaging in the differential diagnosis of thymoma and mediastinal lymphoma.

Br J Radiol 2018 Dec 3:20180598. Epub 2018 Dec 3.

1 Department of Radiology, Lanzhou University Second Hospital , Lanzhou , PR China.

Objective:: To investigate the imaging characteristics of thymoma and mediastinal lymphoma using spectral CT and evaluate whether the quantitative information can improve the differential diagnosis of these diseases.

Methods:: This retrospective study was approved by the institutional review board, and written informed consent was obtained from all patients. Overall, 39 patients with mediastinal tumors (24 thymomas and 15 mediastinal lymphomas) were examined with CT spectral imaging during the arterial phase (AP) and venous phase (VP). Read More

View Article
December 2018

Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder: Where do we stand? A systematic review.

Authors:
Eman Salah

J Dtsch Dermatol Ges 2018 Dec 3. Epub 2018 Dec 3.

Department of Dermatology, Venereology & Andrology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.

Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder (PCSMP-TLPD) is a provisional entity with uncertain malignant potential according to the latest revision of the WHO classification for lymphoid neoplasms. We conducted a systematic literature review of all previously reported cases of PCSMP-TLPD to highlight their typical and atypical features. The main features of PCSMP-TLPD and its possible clinicopathologic overlap with similar disorders are also discussed. Read More

View Article
December 2018
1 Read

Overexpression of microRNA-98 inhibits cell proliferation and promotes cell apoptosis via claudin-1 in human colorectal carcinoma.

J Cell Biochem 2018 Dec 2. Epub 2018 Dec 2.

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.

Colorectal carcinoma (CRC) is a major cause of cancer-related deaths worldwide, and investigations on novel targets are imperative. MiR-98 has been reported to act as a tumor suppressor in several cancers. To evaluate miR-98 as a novel anticancer molecule for CRC, examinations to validate whether miR-98 conferred an inhibiting effect on proliferation, migration, and invasion were performed. Read More

View Article
December 2018

High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.

Br J Haematol 2018 Dec 2. Epub 2018 Dec 2.

Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Plasma cells are important prognostic actors in different malignancies. The tumour microenvironmental composition in classic Hodgkin lymphoma (cHL) is a major prognostic key element; however, clinicopathological studies regarding plasma cells in cHL are lacking. The aim of this study was to investigate CD138+ (also termed SDC1+) plasma cell and IgG4 producing (IgG4+) plasma cells infiltration in the microenvironment of cHL. Read More

View Article
December 2018

Downregulating STAT1/caspase-3 signaling with fludarabine to alleviate progression in a rat model of steroid-induced avascular necrosis of the femoral head.

J Biochem Mol Toxicol 2018 Dec 1:e22265. Epub 2018 Dec 1.

Department of Orthopaedic, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

Steroid-induced avascular necrosis of the femoral head (SANFH) is mainly induced by glucocorticoids. Fludarabine (Flu) is a specific signal transducer and activator of transcription 1 (STAT1) inhibitor. In this study, we investigated the effect of Flu on SANFH and the role played by the STAT1/caspase-3 signaling pathway. Read More

View Article
December 2018

Qualitative and quantitative cytomorphologic features of primary anaplastic lymphoma kinase-positive lung cancer.

Cytopathology 2018 Dec 1. Epub 2018 Dec 1.

Department of Diagnostic Pathology, Nara Medical University, Nara, Japan.

Objective: Anaplastic lymphoma kinase (ALK) positive (+) lung cancers are predictive for response to crizotinib and alectinib. There are many cases of lung cancer in which surgery cannot be performed, and such cases require diagnosis by cytologic specimen or biopsy. Estimating ALK (+) lung cancer from cytomorphology would allow molecular testing to proceed without the waste of a small amount of specimen. Read More

View Article
December 2018

[Imaging characteristics of gastrointestinal neoplastic acute abdomen].

Zhonghua Wei Chang Wai Ke Za Zhi 2018 Nov;21(11):1223-1229

Department of Radiology, Chinese PLA General Hospital, Beijing 100853, China.

Both malignant tumors derived from gastrointestinal tract and metastasis from peritoneal spread, hematogenous dissemination and lymph node can lead to acute abdomen. Such acute abdomen patients have poor prognosis, high mortality, and complex clinical manifestations. It is difficult to make a correct diagnosis in clinical practice. Read More

View Article
November 2018

Cardiac involvement of malignant lymphoma presenting intra-ventricular-wall nodules.

J Echocardiogr 2018 Nov 30. Epub 2018 Nov 30.

Department of Cardiovascular, Kyoto Daiichi Red Cross Hospital, 15-749 Honnmachi, Higashiyama-ku, Kyoto-si, Japan.

View Article
November 2018

Pleural Effusions in Diffuse Large B-Cell Lymphoma: Clinical and Prognostic Significance.

Lung 2018 Nov 30. Epub 2018 Nov 30.

Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, IRBLleida, Lleida, Spain.

Purpose: Pleural effusion (PEs) may complicate diffuse large B-cell lymphomas (DLBCL). However, their real prevalence and prognostic significance have seldom been approached systematically.

Methods: Retrospective single-center evaluation of consecutive patients with DLBCL was conducted. Read More

View Article
November 2018

Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?

Transl Lung Cancer Res 2018 Dec;7(6):682-690

Department of Cellular Pathology/Molecular Pathology, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

The selection of patients for immunotherapy remains challenging given the lack of highly specific and highly sensitive biomarkers. Nevertheless, it is essential that testing laboratories are able to fulfil licencing criteria by providing the tests which have been validated as providing useful predictive information. Programmed cell death protein 1 (PD-1) expression assessment is now established in routine practice, although the situation regarding the selection of a particular assay remains complex, and testing protocols are likely to change in future. Read More

View Article
December 2018
1 Read

MRI findings, including diffusion-weighted imaging and apparent diffusion coefficient value, in two cats with nasopharyngeal polyps and one cat with lymphoma.

JFMS Open Rep 2018 Jul-Dec;4(2):2055116918812254. Epub 2018 Nov 27.

Department of Advanced Clinical Medicine, School of Life and Environmental Sciences, Osaka Prefecture University, Izumisano, Osaka, Japan.

Objectives: Most nasopharyngeal masses in cats are lymphomas or polyps. To our knowledge, there is no report of MRI findings, including diffusion-weighted imaging (DWI) or apparent diffusion coefficient (ADC) values, of nasopharyngeal lymphomas and nasopharyngeal polyps in cats. This study aimed to evaluate the MRI findings of nasopharyngeal lymphomas and nasopharyngeal polyps, including DWI and ADC values. Read More

View Article
November 2018

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Front Immunol 2018 16;9:2431. Epub 2018 Nov 16.

Department of Haematooncology, University Hospital Ostrava, Ostrava, Czechia.

The treatment of cancer, especially of various types of solid tumors, has been revolutionized by the blockade of the PD-1/PD-L1 pathway by immune checkpoint inhibitors. Their success amongst hematologic malignancies, however, has been limited so far to the treatment of classic Hodgkin's lymphoma, which portrays a typical overexpression of PD-1 ligands (PD-L1, PD-L2) as a consequence of changes in chromosome 9p24.1. Read More

View Article
November 2018
1 Read

miR-10b Downregulated by DNA Methylation Acts as a Tumor Suppressor in HPV-Positive Cervical Cancer via Targeting Tiam1.

Cell Physiol Biochem 2018 Nov 30;51(4):1763-1777. Epub 2018 Nov 30.

Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou,

Background/aims: microRNAs (miRNAs) are known to act as oncogenes or tumor suppressors in diverse cancers. Although miR-10b is an oncogene implicated in many tumors, its role in cervical cancer (CC) remains largely unclear. Here, we investigated the function and underlying mechanisms of miR-10b in human CC. Read More

View Article
November 2018
1 Read

[Application of Lectin from Catfish Eggs to Cancer Therapy: A Fundamental Study].

Authors:
Shigeki Sugawara

Yakugaku Zasshi 2018 ;138(12):1451-1459

Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University.

Silurus asotus egg lectin (SAL) is an α-galactoside-binding protein, isolated from the egg of catfish. It belongs to the rhamnose-binding lectin family that binds to Gb3 glycan (Galα1-4Galβ1-4Glc). SAL has resulted in the induction of early apoptosis in the Raji cell line, which is a Burkitt's lymphoma cell line expressing Gb3. Read More

View Article
January 2018

Richter transformation in the era of novel agents.

Authors:
Wei Ding

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):256-263

Chronic Lymphocytic Leukemia Group, Division of Hematology, Mayo Clinic, Rochester, MN.

Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. Read More

View Article
November 2018

Where does PD-1 blockade fit in HL therapy?

Authors:
Alex F Herrera

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):213-220

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.

Genetic alterations of the / locus on chromosome 9p24.1 are a defining biological feature of classical Hodgkin lymphoma (HL). The resulting programmed death-ligand 1 (PD-L1) expression on Hodgkin Reed-Sternberg cells as well as the PD-L1 expressed in the HL microenvironment result in an ineffective host antitumor immune response and make HL a ripe target for programmed cell death-1 (PD-1) blockade. Read More

View Article
November 2018
1 Read

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):207-212

Memorial Sloan Kettering Cancer Center, New York, NY.

The US Food and Drug Administration approval of brentuximab vedotin (BV) in 2011 marked an important milestone in the management of classical Hodgkin lymphoma (HL). Although initially approved for use in the relapsed or refractory setting, its high efficacy and favorable toxicity profile led to numerous studies evaluating BV in the front-line, second-line, and posttransplant settings. BV is now approved for use (in combination with chemotherapy) as frontline treatment of advanced-stage patients and as maintenance therapy following autologous stem cell transplant. Read More

View Article
November 2018

Risk-adapted therapy for advanced-stage Hodgkin lymphoma.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):200-206

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA.

More than 80% of patients with advanced-stage Hodgkin lymphoma are now cured with contemporary treatment approaches. The ongoing challenge is how to further improve outcomes by identifying both high-risk patients who may benefit from more intensive frontline therapy to reduce the risk of relapse as well as lower-risk patients who may do just as well with less intensive therapy. Numerous trials have used an interim positron emission tomography (PET) response-adapted approach to evaluate early escalation or deescalation of therapy for patients with a positive or negative interim PET scan, respectively. Read More

View Article
November 2018
1 Read

Novel immunotherapy approaches to follicular lymphoma.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):194-199

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Follicular lymphoma (FL) remains a lymphoma subtype that is remarkably sensitive to immunotherapy-based treatment strategies. Anti-CD20 antibody therapy administered as a single agent and in combination as a first-line treatment and at relapse continues to be the most broadly used therapy for this disease. Autologous and allogeneic stem cell transplantation provide meaningful durable remissions for patients with FL. Read More

View Article
November 2018

Sequencing of therapies in relapsed follicular lymphoma.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):189-193

Division of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY.

Follicular lymphoma (FL) is an incurable but treatable disease with vast treatment options. Despite the abundance of efficacious treatment modalities, there is no universally agreed upon standard approach to treatment, particularly in the relapsed/refractory setting. There is an increasing need for more robust and clinically available tools to risk-stratify patients and identify those likely to experience early relapse, which is currently recognized as the unmet need in FL. Read More

View Article
November 2018
1 Read

Where to start? Upfront therapy for follicular lymphoma in 2018.

Hematology Am Soc Hematol Educ Program 2018 Nov;2018(1):185-188

Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.

The initial approach to the management of follicular lymphoma (FL) is challenging for patients and physicians. Most FL patients present with minimal symptoms; given the lack of a survival benefit to early treatment in this population, a period of observation without therapy is often appropriate. Once there is disease progression beyond low-tumor-burden criteria or symptoms prompting intervention, patients may be considered for an array of potential treatment options. Read More

View Article
November 2018
1 Read